Pliant Therapeutics Inc
NASDAQ:PLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pliant Therapeutics Inc
Total Current Liabilities
Pliant Therapeutics Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
Total Current Liabilities
$16.4m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
Pliant Therapeutics Inc
Glance View
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
See Also
What is Pliant Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
16.4m
USD
Based on the financial report for Dec 31, 2025, Pliant Therapeutics Inc's Total Current Liabilities amounts to 16.4m USD.
What is Pliant Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
7%
Over the last year, the Total Current Liabilities growth was -51%. The average annual Total Current Liabilities growth rates for Pliant Therapeutics Inc have been -12% over the past three years , 7% over the past five years .
